Thermo Fisher ScientificTMO
TMO
About: Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of mid-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (22%); and lab products and services, which includes CRO services (54%).
Employees: 122,000
0
Funds holding %
of 7,139 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
26% more first-time investments, than exits
New positions opened: 239 | Existing positions closed: 190
0.98% less ownership
Funds ownership: 88.73% [Q3] → 87.75% (-0.98%) [Q4]
3% less funds holding
Funds holding: 2,523 [Q3] → 2,457 (-66) [Q4]
16% less capital invested
Capital invested by funds: $208B [Q3] → $176B (-$32.4B) [Q4]
19% less repeat investments, than reductions
Existing positions increased: 844 | Existing positions reduced: 1,045
27% less call options, than puts
Call options by funds: $1.06B | Put options by funds: $1.44B
38% less funds holding in top 10
Funds holding in top 10: 115 [Q3] → 71 (-44) [Q4]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$650
22%
upside
Avg. target
$671
26%
upside
High target
$715
34%
upside
7 analyst ratings
5 positive
71%
2 neutral
29%
0 negative
0%
Scotiabank Sung Ji Nam 39% 1-year accuracy 9 / 23 met price target | 22%upside $650 | Sector Perform Maintained | 3 Feb 2025 |
Raymond James Andrew Cooper 14% 1-year accuracy 2 / 14 met price target | 25%upside $667 | Outperform Reiterated | 3 Feb 2025 |
Citigroup Patrick Donnelly 33% 1-year accuracy 10 / 30 met price target | 22%upside $650 | Neutral Maintained | 31 Jan 2025 |
UBS Dan Leonard 43% 1-year accuracy 3 / 7 met price target | 34%upside $715 | Buy Maintained | 31 Jan 2025 |
Wells Fargo Brandon Couillard 14% 1-year accuracy 3 / 22 met price target | 28%upside $680 | Overweight Maintained | 31 Jan 2025 |
Financial journalist opinion
Based on 19 articles about TMO published over the past 30 days
Neutral
CNBC Television
2 days ago
Final Trades: Exxon Mobil, Thermo Fisher and Cheniere Energy
The Investment Committee give you their top stocks to watch for the second half.
Neutral
Business Wire
3 days ago
Thermo Fisher Scientific Increases Quarterly Dividend
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.43 per common share, payable on April 15, 2025, to shareholders of record as of March 14, 2025. This reflects an 10% increase over the previous dividend payment of $0.39. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $4.
Neutral
Business Wire
3 days ago
Thermo Fisher Scientific Elects New Director to Board
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced Karen S. Lynch has been elected to its board of directors, effective February 19, 2025. The appointment brings the total number of Thermo Fisher board members to 12. Ms. Lynch is a seasoned health care executive with over three decades of experience in the industry. As the former president and chief executive officer of CVS Health Corporation (NYSE: CVS), a leading hea.
Positive
Zacks Investment Research
1 week ago
TMO Stock Set to Gain From The Launch of New Spatial Imaging System
Thermo Fisher's Invitrogen EVOS S1000 Spatial Imaging System addresses the limitations of current fluorescent microscopy technologies.
Neutral
Business Wire
1 week ago
Thermo Fisher Scientific's New Spatial Imaging System Enables Researchers to Generate High-quality Data, Making it Easier to Enter the Field of Spatial Tissue Proteomics
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Invitrogen™ EVOS™ S1000 Spatial Imaging System. This advanced system addresses the limitations of current fluorescent microscopy technologies by enabling researchers to generate a multiplexed high-quality image for multiple samples within several hours, thereby lowering the barrier to entry into spatial tissue proteomics. The EVOS S1000, from Thermo Fisher Scientific's innov.
Neutral
GlobeNewsWire
1 week ago
Laboratory Supplies Market Analysis 2022-2024 and Forecast 2025-2030, Featuring Profiles of Key Players - Th. Geyer, Thermo Fisher, Spectrum Chemical Manufacturing Corp., Ing.
Dublin, Feb. 12, 2025 (GLOBE NEWSWIRE) -- The "Laboratory Supplies Market - Forecasts from 2025 to 2030" report has been added to ResearchAndMarkets.com's offering. The global laboratory supplies market is projected to grow at a CAGR of 7.44% over the forecast period, increasing from US$47.531 billion in 2025 to US$68.044 billion by 2030. The laboratory supply market is expanding due to advancements in science and technology, along with increased research and development (R&D) activities. In the healthcare and pharmaceutical sectors, the rising demand for high-quality, specialized supplies - particularly in genomics, proteomics, and biotechnology - further drives the growth of this market. Additionally, the emphasis on laboratory automation and sustainability has led to the development of more efficient, eco-friendly, and cost-effective laboratory products. Key Drivers of the Laboratory Supplies Market
Neutral
Business Wire
2 weeks ago
Thermo Fisher Scientific Launches International CorEvitas Clinical Registry in Adolescent Alopecia Areata
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. announced the launch of the international CorEvitas Adolescent Alopecia Areata (AA) Registry.
Neutral
Business Wire
2 weeks ago
Thermo Fisher Scientific Accelerates 100 Percent Renewable Electricity Goal for European Operations with New Solar Power Agreement with X-ELIO
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced a 10-year virtual power purchasing agreement (VPPA) with international renewable energy developer X-ELIO designed to increase access to renewable electricity across the pharmaceutical and healthcare supply chains. The Lorca solar project is expected to be operational in early 2026 and includes a cohort of three partners from the pharmaceutical and healthcare sectors.
Positive
Seeking Alpha
3 weeks ago
Thermo Fisher Scientific: Finally Ready For A Breakout? (Upgrade)
Thermo Fisher returned to growth in 4Q 2024 across all segments, and 2025 EPS growth is projected at 6.6% supported by margin expansion. Despite rich industry valuations, Thermo trades at a discount to peers like Danaher, supported by its unique scale and breadth of offerings. Thermo looks fairly valued based on a conservative DCF analysis, but its industry leadership position and relative valuation to peers warrant an upgrade to Buy.
Positive
Investopedia
3 weeks ago
Thermo Fisher Stock Surges as Medical Device Maker's Results Top Estimates
Shares of Thermo Fisher Scientific (TMO) rose Thursday after the medical device maker's fourth-quarter results topped analysts' estimates.
Charts implemented using Lightweight Charts™